Ryan Bitton, PharmD, MBA

Types of patients who will likely benefit from long-acting injectable PrEP therapies in the HIV treatment pipeline.

An overview of HIV PrEP therapies in the pipeline and their potential roles as they are introduced into the community for use among high-risk populations.

Updates to the US Preventive Services Task Force grade A recommendation for HIV PrEP therapy and payer response to supporting providers and pharmacists who prescribe therapies used as prophylaxis.

Discussion regarding HIV PrEP walkaway rates and strategies that can help support patients and increase adherence to therapy.

Payer perspective regarding strategies that can be deployed to help improve the patient/provider experience and utilization of PrEP therapy as prophylaxis against HIV.